This article will focus on the Ultra-Fast-Acting Insulin segment as a whole and specifically, we will examine the recent trial data from Biodel (BIOD), a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes a growing therapeutic area worldwide and a $10-$12 billion segment in the US alone.
Advantages of Ultrafast insulin (there are many)
A) Better glycemic control
Faster, higher insulin concentrations and peak exposure (i.e., fast in) results in early glucose lowering effects and reduced post-meal hyperglycemia, which may lead to better A1C control
B) Less hypoglycemia
Reduced late post-meal exposure (i.e., fast out) may result in fewer hypoglycemic events
C) Less weight gain (a huge plus)
Fewer hypoglycemic events and
Only subscribers can access this article, which is part of the PRO research library covering 3,760 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: